Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Guggenheim Maintains Buy on Celldex Therapeutics, Lowers Price Target to $63

Guggenheim Maintains Buy on Celldex Therapeutics, Lowers Price Target to $63

Guggenheim analyst Yatin Suneja maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $68 to $63.

byBenzinga Newsdesk

November 11, 2022

1 minute read

Guggenheim analyst Yatin Suneja maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $68 to $63.

Analyst Ratings

Analyst Ratings for Glaukos

By Benzinga Insights

July 31, 2:00 PM

Analysts have provided the following ratings for Glaukos (NYSE:GKOS) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

GKOS

News

Meta Has Begun Cutting Significant Numbers of Employees Through Restructuring, Sources Say

By Charles Gross

September 21, 12:49 PM

-Wall Street Journal

Analyst Expectations for Best Buy Co’s Future

By Benzinga Insights

December 11, 2:00 PM

Analysts have provided the following ratings for Best Buy Co (NYSE:BBY) within the last quarter: Bullish Somewhat Bullish…

BBY

OP Bancorp Q2 EPS $0.54 Up From $0.42 YoY, Sales $12.94M Down From $16.81M YoY

By Michael Horton

July 28, 4:42 PM

OP Bancorp (NASDAQ:OPBK) reported quarterly earnings of $0.54 per share. This is a 28.57 percent increase over earnings of $0.42 per share from the same period last year. The company reported $12.94 million in sales

OPBK

Guggenheim Maintains Buy on Celldex Therapeutics, Lowers Price Target to $63

Related Posts

Analyst Ratings for Glaukos

Meta Has Begun Cutting Significant Numbers of Employees Through Restructuring, Sources Say

Analyst Expectations for Best Buy Co’s Future

OP Bancorp Q2 EPS $0.54 Up From $0.42 YoY, Sales $12.94M Down From $16.81M YoY